ESCAPE Bio is a clinical-stage, privately-held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases. ESB1609 is in a Phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of escalating multiple doses in healthy volunteers. ESCAPE's pipeline includes small molecules targeting known genetic drivers of CNS disorders, including ESB1609, an S1P5 agonist for the treatment of CNS lysosomal storage disorders and GBA Parkinson's; a G2019S-selective kinase inhibitor for Parkinson's Disease (PD) patients with that mutation; and an Alzheimer's disease program targeting ApoE4.
| Website | http://www.escapebio.com |
| Revenue | $15 million |
| Funding | $182 million |
| Employees | View employees |
| Address | 4000 Shoreline Ct Ste 400, South San Francisco, California 94080, US |
| Phone | (650) 431-0000 |
| Industry | Business Services General, Business Services |
| Competitors | Amgen, Gilead Sciences, Vertex Pharmaceuticals, Illumina, Genentech, Biogen, Regeneron, Alnylam Pharmaceuticals, Moderna Therapeutics, Sarepta Therapeutics, Inc. +39 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular E-Scape Bio Inc employee's phone or email?
E-Scape Bio Inc Questions
The E-Scape Bio Inc annual revenue was $15 million in 2026.
E-Scape Bio Inc is based in South San Francisco, California.
The NAICS codes for E-Scape Bio Inc are [54, 54171, 5417, 541, 541713].
The SIC codes for E-Scape Bio Inc are [873, 87].
